A new breakthrough from the University of Saskatchewan could potentially reduce the labor-intensive calving season for beef producers. Cetrorelix, a hormone drug commonly used in human IVF treatments, has shown promise in helping synchronize ovulation in cattle, leading to a more efficient and synchronized calving process.
Dr. Jaswant Singh, a veterinarian and researcher at the university, along with graduate students Dylan Farmer and Carlos Leonardi, discovered the effectiveness of Cetrorelix in a study conducted eight years ago. The drug’s ability to induce pregnancy in cows within a short timeframe could significantly streamline the calving period, resulting in cost savings and improved management of the animals.
Garner Deobald, a beef rancher and marketing manager at BoviGen Genetic Services, expressed enthusiasm about the potential benefits of Cetrorelix for enhancing cattle reproduction practices. The drug’s ability to enhance artificial insemination could lead to better genetic selection and more accurate calf expectations, making it an attractive option for farmers seeking improved breeding techniques.
The university has filed for a patent on Cetrorelix and is collaborating with pharmaceutical companies to bring the drug to market. Dr. Singh is optimistic about the widespread adoption of the drug in the agricultural industry, anticipating increased usage of artificial insemination techniques globally. The drug’s affordability and positive results in animal trials position it as a promising solution for enhancing cattle breeding practices.
